BeiGene Ltd
(HKSE:06160)
HK$
129.8
-4 (-2.99%)
Market Cap: 186.24 Bil
Enterprise Value: 180.29 Bil
PE Ratio: 0
PB Ratio: 6.72
GF Score: 83/100 Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022 / 02:00PM GMT
Release Date Price:
HK$133.4
(+5.12%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Welcome. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim and it is my great pleasure to welcome the next company, BeiGene. With us today, we have John Oyler, Co-Founder and CEO. John, thanks so much for joining us and welcome.
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Thanks, happy to be here.
Questions & Answers
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So I think I'll just start with a big picture question. BeiGene is obviously now one of the largest global biotech companies. Perhaps, John, if you -- could you briefly just highlight how the strategy of the company has been in recent years?
John V. Oyler
BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Sure. Happy to do that. I think BeiGene started about 12 years ago. And from the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot